The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Technology and Consumer Discretionary are the only two sectors down in the first two months of this year, among the 11 market ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was ...